Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antidepressant medications: three SSRIs (citalopram, paroxetine, and sertraline) and one SNRI (venlafaxine). While these medications are not typically prescribed all together simultaneously, they represent different options that may be used in combination therapy strategies for treatment-resistant depression.\n\nThe search results indicate that combinations of SSRIs with SNRIs (particularly venlafaxine) have been studied, though usually as pairs rather than all four medications together. The rationale for such combinations is to provide additional serotonergic activity plus adrenergic activity by targeting multiple neurotransmitter systems.\n\nEach component has distinct properties:\n- Citalopram: An SSRI with relatively minimal drug interaction potential due to limited CYP enzyme inhibition\n- Paroxetine: An SSRI that is a potent inhibitor of CYP2D6, which can affect metabolism of other drugs\n- Sertraline: An SSRI with some dopaminergic activity in addition to its serotonergic effects\n- Venlafaxine: An SNRI that acts on both serotonin and norepinephrine reuptake, with dose-dependent effects (more SSRI-like at lower doses)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citalopram, Paroxetine, Sertraline, and Venlafaxine Combination.